Royalty Pharma Reports Strong Q3 2026 Results and Raises Full-Year Guidance
Royalty Pharma (RPRX) reported robust third-quarter 2026 financial results, characterized by a 9% year-over-year increase in portfolio receipts to $890 million. The company's growth was driven by strong performance across key assets, including Tremfya and Voranigo, alongside the successful integration of new royalties such as Evrysdi. Reflecting this momentum, management raised its full-year 2026 portfolio receipts guidance to a range of $3.5 billion to $3.55 billion for the third consecutive quarter. The company also increased its royalty receipts growth guidance to 10%-11%. With $4.8 billion in financial flexibility and significant capital deployment underway, Royalty Pharma continues to focus on high-margin biopharmaceutical royalties while maintaining strong shareholder returns through dividends and buybacks.
Topics: financial guidance pharmaceutical royalties portfolio performance royalty revenue